Studies of the clonal architecture of gastric glands with intestinal metaplasia are important in our understanding of the progression from metaplasia to dysplasia. It is not clear if dysplasias are derived from intestinal metaplasia or how dysplasias expand. We investigated whether cells within a metaplastic gland share a common origin, whether glands clonally expand by fission, and determine if such metaplastic glands are genetically related to the associated dysplasia. We also examined the clonal architecture of entire dysplastic lesions and the genetic changes associated with progression within dysplasia. METHODS: Cytochrome c oxidase-deficient (CCO Ϫ ) metaplastic glands were identified using a dual enzyme histochemical assay. Clonality was assessed by laser capture of multiple cells throughout CCO Ϫ glands and polymerase chain reaction sequencing of the entire mitochondrial DNA (mtDNA) genome. Nuclear DNA abnormalities in individual glands were identified by laser capture microdissection polymerase chain reaction sequencing for mutation hot spots and microsatellite loss of heterozygosity analysis. RE-SULTS: Metaplastic glands were derived from the same clone-all lineages shared a common mtDNA mutation. Mutated glands were found in patches that had developed through gland fission. Metaplastic and dysplastic glands can be genetically related, indicating the clonal origin of dysplasia from metaplasia. Entire dysplastic fields contained a founder mutation from which multiple, distinct subclones developed. CONCLUSIONS: There is evidence for a distinct clonal evolution from metaplasia to dysplasia in the human stomach. By field cancerization, a single clone can expand to form an entire dysplastic lesion. Over time, this field appears to become genetically diverse, indicating that gastric cancer can arise from a subclone of the founder mutation.
G astric adenocarcinoma (GA) is a major cause of cancer-related mortality worldwide (http://info .cancerresearchuk.org/cancerstats; Cancer Research UK, 2010, London, UK, viewed 6th March 2011). There are a multitude of risk factors: within these, infection with Helicobacter pylori and the development of intestinal metaplasia (IM) are prominent. 1,2 IM of the human stomach is the replacement of the normal gastric glands with an intestinal crypt phenotype. Current dogma proposes that there is a stepwise progression from chronic atrophic gastritis to intestinal metaplasia, with subsequent progression to low-/high-grade dysplasia, eventually culminating in the intestinal type of GA. 3, 4 Using whole tissue specimens, previous studies have suggested that metaplasia can contain similar genetic abnormalities to the associated GA, 3, [5] [6] [7] suggesting that IM is a premalignant condition from which a carcinoma may develop. Whereas some studies demonstrate a genetic link, 7 some reported abnormalities were also present in adjacent normal tissue and were therefore most probably polymorphisms. 3 To date, a clear genetic link, on a gland-by-gland basis, describing the evolution of metaplasia into dysplasia has not been produced.
The clonal nature of metaplastic glands in the human stomach is a source of some controversy. We have previously shown that human IM glands from patients undergoing resection for GA can be entirely deficient in cytochrome c oxidase (CCO). 8 This deficiency has been shown to be highly suggestive of an underlying mutation in the mitochondrial genome resulting in CCO deficiency; therefore, IM glands from the human stomach appear clonal. Other groups have suggested otherwise; Mihara et al 9 demonstrated that, within single IM glands, patterns of CpG methylation in the promoter regions of the ZIK1 gene, which is normally silenced in the human stomach, are highly polymorphic, suggesting that metaplastic glands develop multifocally, arising from multiple stem cells. On the other hand, methylation patterns are known to change over time, and the variability observed by Mihara et al 9 may reflect rapid diversification rather than stable clones. To understand the progression and expansion of intestinal metaplasia and its relationship to dysplasia, the stem cell and clonal architecture of IM become important.
Early gastric intestinal type adenocarcinomas are usually associated with fields of dysplastic glands. 10 Again, it is unknown how these fields develop and spread through the stomach, namely whether by multiple dysplasia-initiating events occurring independently or through extensive clonal expansion of a single dysplastic gland through a large area of gastric mucosa. There is precedent for both scenarios in the human gastrointestinal tract: in patients with ulcerative colitis-associated neoplasias, a single mutated crypt is able to spread through large areas of colonic mucosa encompassing the entire lesion, 11 a socalled founder mutation. On the other hand, Barrett's esophagus appears to be a genetically heterogeneous disease where there are multiple clones within the Barrett's mucosa. 12 Even leaving aside the intrinsic interest of the true nature of the development of intestinal-type gastric carcinoma, the lack of such knowledge severely impairs our ability to identify reliable biomarkers to assess the risk of gastric carcinogenesis.
Here, we show, by using either cell-by-cell or gland-bygland laser capture microdissection of human gastric epithelium that intestinal metaplastic glands are clonal, the intestinal metaplasia clonally expands by crypt fission to form large patches, and that dysplasia can arise from a single clone of mutated intestinal metaplastic glands and expand to form the entire dysplastic lesion. Furthermore, we show that, within this clonal dysplastic field, genetic diversity can arise, raising the possibility that cancer develops through genetic progression of a subclone arising from the founder mutation.
Patients and Methods Patients
Intestinal metaplastic and dysplastic formalinfixed, paraffin-embedded and frozen specimens were obtained from patients undergoing resection for either GA or high-grade dysplasia and from pathology archives. A total of 23 patient specimens (age range, 57-72 years) were used in this study. Ethical approval was sought and obtained as per United Kingdom Human Tissue Act (2006, reference 07/Q1604/17) and Hikone Municipal Hospital (Japan) regulations. Histology of each specimen was confirmed by 2 pathologists (N.A.W. and M.R.J.). All specimens showed IM surrounding or in between large areas of dysplasia (or early gastric cancer) and was consistent through multiple blocks from each patient.
Laser Capture Microdissection
Ten serial sections (5-20 m) of each specimen were prepared. Sections 1-5 were cut onto normal glass slides, and sections 6 -10 were cut onto P.A.L.M. MembraneSlide 1.0 PEN slides (Zeiss Microimaging, Munich, Germany). Paraffin sections were left overnight at 37°C, dewaxed in xylene, rehydrated through decreasing ethanol concentrations to water, and then air-dried. Frozen sections were allowed to air-dry immediately after cutting. Each membrane section underwent light staining with methylene green (2%; Sigma, Poole, UK). Paraffin sections 1-3 were used to screen for genomic mutations. Sections 4 and 5 were used for H&E or alcian blue/ periodic acid-Schiff/diastase staining. On sections 6 -10, areas of interest were delineated using P.A.L.M. Robosoftware (Zeiss Microimaging) and cut into 0.5-mL AdhesiveCap tubes using a P.A.L.M. Laser capture microdissection system (Zeiss Microimaging). The majority of the frozen sections was used for enzyme histochemistry with an occasional section (approximately 1 per 20 sections cut) used for H&E. Captured specimens were incubated overnight (paraffin) or 3 hours (frozen) in PicoPure DNA extraction buffer (Arcturus Bioscience, Mountain View, CA) and were then denatured at 95°C for 10 minutes.
Enzyme Histochemistry
Sections of frozen gastric mucosa were subjected to a dual enzyme histochemical staining to assay activity for CCO and succinate dehydrogenase as per published protocols. 13, 14 Briefly, sections were incubated in 0.2 mol/L phosphate buffer (pH 7.0) containing 100 mmol/L cytochrome c, 4 mmol/L diaminobenzidine tetrahydrochloride, and 20 g/mL catalase (All Sigma, Poole, UK) for approximately 50 minutes at 37°C in a humid chamber. Sections were washed 3 times for 5 minutes each in phosphate-buffered saline (PBS; Sigma) then incubated in 0.2 mol/L phosphate buffer (pH 7.0) containing 130 mmol/L sodium succinate, 200 mmol/L phenazine methosulfate, and 1.5 mmol/L nitroblue tetrazolium (all Sigma) for 45 to 90 minutes at 37°C until a blue color develops. Sections were then washed in PBS 3 times for 5 minutes and dehydrated through increasing ethanol concentrations and left in 100% ethanol for 10 minutes and allowed to dry. Sections that were stained on normal glass slides were mounted in Permount (Fisher Scientific, Fairlawn, NJ) and then coverslipped.
Immunohistochemistry
Immunohistochemistry was performed by formalin-fixed, paraffin-embedded sections as per previously published protocols. 8 
Mitochondrial DNA Polymerase Chain Reaction Sequencing
The entire mitochondrial genome was sequenced in cells laser captured from frozen sections. To get sufficient product to sequence, a 2-round, nested polymerase chain reaction (PCR) protocol that amplified the entire mitochondrial DNA (mtDNA) in a series of overlapping fragments was used as per previous publications detailing primer sequences. 14, 15 Briefly, the mitochondrial genome was amplified in overlapping fragments by using a series of M13-tailed oligonucleotides. PCR products were sequenced by using BigDye3.1 terminator cycle sequencing chemistries on an ABI Prism 3730 DNA Analyzer (Applied Biosystems, Foster City CA) and compared directly with the revised Cambridge mtDNA reference sequence. Variations in the sequences of CCO-deficient cells, not present in neighboring CCO-normal cells, were considered to be clonal markers. All sequencing was repeated 3 times.
Genomic PCR Sequencing
To screen for genomic DNA mutations, areas of dysplasia were identified on an H&E section, which was then traced onto the 3 preceding serial, dewaxed but unstained serial sections. Needle macrodissection of these areas was digested in 30 L PicoPure as described above. The lysate was used to screen for mutations in APC (adenamtous polyposis coli mutation cluster region), TP53 (exons 5-8), KRAS (codons 12 and 13), CTNNB1 (␤-catenin, exon 11), CDKN2A (p16, exon 2), and PTEN (phosphatase and tensin homolog exons 5, 6, and 8). These genes account for approximately 85% of all somatic mutations previously reported in gastric adenocarcinomas according to the catalogue of somatic mutations in cancer (COSMIC) database (www.sanger .ac.uk/genetics/cgp/cosmic). Most mutations within the COSMIC database have been identified in cancer specimens and may be late events in the dysplasia:carcinoma sequence. After a mutation had been detected in tissue lysate, every laser-captured gland would then be screened individually for that mutation using a nested PCR protocol. Primers and PCR reaction conditions can be found in Supplementary Table1. DNA extracted from each gland was divided into 2 separate tubes to repeat each sequencing reaction. Furthermore, single cells were laser captured and subjected to PCR and sequencing for each gene. These were entirely unsuccessful, and, therefore, the contribution of any contaminating cells that were extraneous to each lasercaptured gland was negligible.
Loss of Heterozygosity Analysis
Loss of heterozygosity (LOH) analysis was performed on individual gland lysates using a multiplexed microsatellite assay. Sixteen highly polymorphic microsatellites, located on chromosomes 3p (FHIT), 5q (APC), 9p (CDKN2A), 17p (TP53), 17q, and 18q (SMAD4), were amplified in 4 separate reactions using a multiplex PCR kit (Qiagen, Crawley, UK). Amplification of constitutional and individual gland lysate was done in parallel to control for PCR variability. Constitutional DNA was extracted from normal smooth muscle. Marker accession numbers and primer and reaction details are shown in Supplementary Table 2. Primers were tagged at the 5= end with either a FAM (tetrachloro-6-carboxyfluorescin) or HEX (hexachloro-6-carboxyfluorescin) fluorescent marker. Successfully amplified PCR products were analyzed on an ABI 3100 Genetic analyser (Applied Biosystems) using Genotyper 2.5 software (Applied Biosystems). LOH was then considered present if the area under 1 allelic peak was more than twice that of the other, after normalizing the peak areas relative to the constitutional DNA.
Mapping of Genomic Abnormalities
All laser-captured glands were genotyped for the mutation discovered in the screening phase and analyzed for LOH at informative markers. Using an H&E image of the serial section to a postlaser-captured section as a guide, topographical maps of mutation spread were created with each phenotype and genotype assigned a unique color code.
Results

Intestinal Metaplastic Glands Are Clonal
To determine the clonal architecture of intestinal metaplastic glands, sections of snap-frozen gastric resection tissue were assayed by dual-enzyme histochemistry for CCO activity. Cells from glands that were entirely CCO deficient (blue, Figure 1A ) were laser captured from the base to the surface of the gland ( Figure 1B and C) . Sequencing revealed the same mutation (7588GϾA within the cytochrome c oxidase subunit II [MT-CO2] gene) in every CCO-deficient region captured, whereas sequencing cells captured along the length of a neighboring CCO-normal gland revealed an entirely wild-type genotype ( Figure 1D and E and Supplementary Figure 1) . This provides conclusive evidence that intestinal metaplastic glands from the human stomach are indeed clonal.
We observed a large patch of approximately 15 CCOdeficient metaplastic glands (Figure 2A ), surprising because of the rarity of such CCO-deficient glands within the gastric mucosa. Sequencing the mitochondrial genome from cells taken from this large patch of CCOdeficient metaplastic glands revealed that each individual gland within the patch contained the same mutation (8503CϾT within the mitochondrially-encoded 16S RNA (MT-RNR2) gene, Figure 2A-C) . The surrounding CCOnormal glands did not contain this mutation ( Figure 2D ). We therefore conclude that every metaplastic gland within this patch is clonally derived from the same founder gland.
Dysplasia Can Originate From Metaplasia in the Human Stomach
To investigate the origins of dysplasia within the human stomach, areas of dysplasia in each specimen were needle macrodissected and screened for mutations in genes known to be mutated in GA. In 23 patients screened, 3 (all of Japanese origin) showed a mutation common to both metaplasia and dysplasia. In patient 1, a c.4680insA mutation in APC was found in 7 of 42 metaplastic glands. showed that 5 of 78 metaplastic glands shared the same mutation as the surrounding dysplasia and that, in patient 3 (c.643GϾA mutation in TP53), there were 3 of 72 mutated metaplastic glands. This is summarized in Supplementary Table 3 .
Whole Tissue Clonal Analysis Reveals a Founder Mutation in Fields of Dysplasia
To determine how dysplasia develops and spreads in the human stomach, numerous glands of varying phenotypes were individually laser-capture microdissected and mapped according to their genotype. In patient 2, the spatial location of the c.4688insA in APC mutation in an area of mucosa displaying metaplasia and dysplasia is shown in Figure 4 . Figure 4A is an H&E (in higher power, 4B), and Figure 4C shows the post-microdissected specimen (serial section to 4A) with the genotype of each gland color mapped. Although a vast majority of metaplastic glands were genetically wild type, the occasional metaplastic gland contained the APC mutation. Importantly, every dysplastic gland contained this mutation. Supplementary Figure 2 demonstrates the mapping of an entire block from patient 1, showing that every dysplastic gland contained a c.4680insA in APC. Patient 3 (c.643AϾG transition in TP53) was also mapped (data not shown). In each of these 3 patients, there was a single founder mutation throughout the dysplastic field (patient 1, 22/22 dysplastic glands; patient 2, 67/67; and patient 3, 158/158). This is compelling evidence, suggesting that the entire dysplastic lesion was derived from a single metaplastic gland. Furthermore, it is clear that this mutation was not the dysplasia-initiating event because mutated metaplastic glands with the same mutation are present. Supplementary Table 3 summarizes all data from these patients. It should be noted that, although 3 informative patients were found, the remaining 20 patients screened did not have a mutation in any of the genes that were screened.
Spasmolytic polypeptide-expressing metaplasia (SPEM) has been implicated as a condition that can either give rise to IM or GA itself. To this end, we have performed immunohistochemistry for trefoil factor 2 (TFF2) in an attempt to detect SPEM. In each specimen TFF2 was detected at the base of normal pyloric glands but was generally absent from metaplastic or dysplastic glands. However, 1 specimen (patient 1, c.4680insA in APC) did show the rare intestinal metaplastic gland that expressed TFF2 (Supplementary Figure 3) .
Genetic Diversity Is Subsequent to Clonal Expansion of the Founder Mutation
To attempt to understand how a field of dysplasia may develop into cancer, genetic diversity was sought within fields of dysplasia by searching for further mutations and LOH within regions of genomic DNA that are associated with genes known to be mutated within gastric cancer. Figure 5A shows a strip of mucosa displaying both metaplasia and dysplasia from patient 1 (c.4680insA in APC).
Figure 5B maps all glands with significant LOH of 2 microsatellite markers associated with TP53. Subclones consisting of 8 of 17 dysplastic glands in this strip of mucosa were identified by their TP53 LoH. Figure 5C shows representative LOH in both microsatellites associated with TP53. Patient 3 showed similar findings, and all 3 patients are summarized in Supplementary Table 4 .
Additional mutations can contribute to genetic diversity within fields of dysplasia. Figure 6 shows in patient 1 (c.4680insA APC founder mutation) isolated groups of p53-positive glands demonstrated by immunohistochemistry. When those p53-positive crypts were laser-capture microdissected, a TP53 mutation was found (c.818 GϾA transition resulting in a p.272RϾH amino acid change). Those neighboring dysplastic glands, which were p53-negative or contained a few p53-positive cells, were TP53 wild type. All other patients with dysplasia displaying founder mutations showed widespread p53 staining, making it impossible to phenotypically identify glands that contain further TP53 mutations. Further attempts to identify further genetic diversity by ␤-catenin immunohistochemistry were unsuccessful because all specimens showed consistent membranous or frequent nuclear staining (Supplementary Figure 4) . Supplementary Table 4 summarizes the genetic diversity found in the 3 informative specimens investigated.
Discussion
Here, we have conclusively demonstrated that metaplastic glands within the human stomach are clonal and can clonally expand through the stomach. Previous work from this laboratory 8 has questioned initial observations by Mihara et al 9 that such glands were polyclonal as defined by methylation signatures of promoters of nonexpressed genes. It is known that CpG methylation does change over time 16 ; moreover, we have shown, using partially CCO-deficient colonic crypts as a marker of clonal expansion, that CpG methylation does record the immediate ancestry of small clones within individual human colonic crypts. As these clones increase in size through the process of niche succession and monoclonal conversion, 13, 17 their methylation signatures quickly diversify, and, by the time a crypt divides into 2 daughter crypts, their methylation signatures are no more similar than crypts distant to each other 18 (unpublished observations) . This suggests that the use of CpG methylation signatures as markers of clonal expansion is likely to be uninformative when considering the clonality of whole glands. We consider that a specific point mutation (here within the mitochondrial genome) is a reliable marker of clonal expansion and that the presence of the same mutation throughout an intestinal metaplastic gland confirms clonality.
Field cancerization is the process by which a field of epithelial cells is preconditioned to allow the development of tumors. 19 It is thought to expand by repeated gland fission events within the gastric mucosa. 8 Gland fission, first proposed by Hattori and Fjuita, 20 is the process by which a gland bifurcates at the neck/isthmus and divides into 2 distinct daughter glands. Here, we describe a large patch of CCO-deficient metaplastic glands, containing approximately 15 glands, each containing the same mtDNA mutation (and therefore derived from a founder gland). Intestinal metaplastic glands of course resemble intestinal crypts rather than gastric glands, but we have shown that clonally mutated patches arise in the human colon also through the mechanism of crypt fission. 13 Individual CCO-deficient metaplastic glands in the stomach are rare when compared with those in the colon. In the normal human colon, the average patch size at the age of the patient we describe here is 2.5 crypts, 13 and it is therefore interesting to observe such a large patch of mutated intestinal metaplastic glands. The reason for this is of course unknown, but it is tempting to relate it to the inflamed microenvironment, 21 a concept supported by the prominent crypt fission seen in patients with active ulcerative colitis. 22 We are limited in this analysis because of the rarity of CCOdeficient glands in the gastric mucosa.
Evidence that metaplasia is an immediate precursor of dysplasia in the human stomach is limited. Previous studies looking at the genetic relationship between the 2 tend to focus on whole tissue DNA analysis investigating individual tumor suppressor genes. 3, 5, 6 This study has, for the first time, attempted to identify genetic abnormalities on a gland-by-gland basis in genes accounting for approximately 85% of nuclear DNA mutations previously reported (COSMIC) in human GA. In our cohort, mutations in these genes were rarely detected strongly, suggesting that, if 2 glands shared the same mutation, they are very likely to have originated from the same gland, regardless of phenotype.
Interestingly, most of the patients in this study displayed no obvious genetic relationship between metaplasia and dysplasia. These patients did not show any mutations in our panel of tumor suppressor genes in their entire and, in many cases, very extensive areas of dysplas- tic mucosa. An explanation to why most specimens do not show this could be that, despite screening the most common genes known to be mutated in GA, there may be as yet undiscovered genes that are mutated are high frequency in GA. Methylation of tumor suppressor gene promoters also plays an important role in carcinogenesis, and this could possibly explain the lack of mutations seen in our early gastric cancer patients. For example, in the esophagus, Eads et al have demonstrated that there is increased promoter methylation in genes such as APC and CDKN2A in the progression of Barrett's esophagus to esophageal adenocarcinoma. 23, 24 Somatic changes in methylation may drive gastric carcinogenesis, and work is underway to address this.
It is also pertinent to consider whether IM is the only pathway to dysplasia. In cases in which a mutation is shared between IM and dysplasia, there is a definite sequence of genetic events that are inherited as the disease progresses, and the origins of dysplasia are clear. We cannot discount the possibility that other, undetected, (epi-)mutations link metaplasia and dysplasia in the cases that were wild type for our panel of genes. However, IM may not be the only precursor of dysplasia, and, in this respect, there is much current interest in SPEM. 25 Our study provides a precedent to perform analogous clonal analysis of concomitant SPEM, IM, and dysplastic lesions to determine the biologic and clinical significance of SPEM plaques.
Large-scale clonal expansion of dysplastic glands has previously been observed in the human gastrointestinal tract. Leedham et al demonstrated that a single mutation was able to spread through an entire lesion of ulcerative colitis-associated neoplasia. 11 However, the existence of founder mutations in a lesion appears to be dependent on the specific lesion. For example, Thirlwell et al 26 have recently shown that colonic adenomas from patients with familial adenomatous polyposis are polyclonal containing multiple clones with distinct patterns of APC inactivation and that, whereas sporadic adenomas frequently contain multiple clones, only one progresses to the resulting invasive carcinoma. Furthermore, genetic heterogeneity is a feature of Barrett's esophagus and is thought to promote tumor progression, 27, 28 although this has been disputed. 29, 30 Dysplasia within the human stomach appears to differ slightly from these examples. There is a clonal proliferation of a single mutated metaplastic gland that eventually becomes dysplastic, and this expands forming an entirely clonal dysplastic lesion. Further genetic abnormalities accrue and expand on top of the founder mutation. We know that these early mutations are not dysplasia-initiating events because, if that were the case, we would not observe any mutated metaplastic glands. We have no evidence to suggest that specific mutations would influence the rate of expansion by fission, although we would predict that, as more genetic abnormalities are acquired, that the fission index would increase.
Analysis of clonal expansion is important when we consider how a premalignant lesion progresses into cancer. The greater the expansion, the greater the probability of acquiring a tumor-initiating defect. Competition between clones has been suggested to be the driving factor of the development of esophageal adenocarcinoma arising from Barrett's esophagus. 27 Such models predict that the more clones present in premalignant lesion, the more likely it will progress to cancer. Does this accord with what is seen in the human gastric mucosa? The answer is that it probably does; however, such clonal competition only arises when a substantial field of genetic heterogeneity exists. Here, we show an entire field of dysplastic glands exhibit a founder mutation. This would indicate that the lesion is clonal and competition between dysplastic glands may not be prominent but rather have a selective advantage over surrounding wild-type metaplastic glands. Over time, genetic diversity does occur with glands exhibiting LOH or additional mutations arising on the back of the founder mutation. Clonal competition could therefore become more of a driving force, and we would predict that lesions with more diversity would be more likely to develop into cancer.
Clonal ordering of genetic abnormalities allows us to describe the genetic ancestry of dysplastic fields and permits the creation of phylogenetic trees (Figure 7) . In this Figure, we show the time line by which each abnormality occurs in each informative patient as they progress from chronic gastritis to metaplasia to dysplasia. It is clear that a vast majority of metaplastic glands are genetically wild type with only a small percentage displaying a mutation. When a mutation does arise in a metaplastic gland, the initiation of dysplasia must occur rapidly because the proportion of mutated metaplastic to dysplastic glands is very small. Although the presence of mutated metaplastic glands indicates that the acquisition of such mutations is not a dysplasia-initiating event, an overwhelming number of mutated glands are nevertheless dysplastic. It is important to note that, although mutated cases are limited in number, we do not think that there is a specific order of mutations within metaplasia:dysplasia sequence and that an APC founder mutation may be as frequently detected as a TP53 founder mutation.
To conclude, these data demonstrate that intestinal metaplastic glands from the human stomach are clonal and can expand by fission. When a mutation within a tumor suppressor gene occurs in an intestinal metaplastic gland, it quickly becomes dysplastic and then expands, rapidly forming a clonal field of dysplasia. Such fields promote the development of additional genetic abnormalities resulting in multiple independent subclones. This process is not apparently universal and may be one of several mechanisms behind the development of gastric carcinogenesis. Patients 1-3 demonstrate our working hypothesis that the dysplasia develops from a mutated metaplastic gland and that every dysplastic gland can trace its ancestry to this metaplastic gland of origin. Over time, genetic diversity can develop, and we hypothesize that the greater the extent of diversity, the more likely cancer will develop. Patient 4 is entirely wild type and accounts for the majority of patients in this study suggesting that there may be mutations in genes hitherto unreported, tumor suppressor genes silenced by methylation, or that dysplasia arises independently of the surrounding metaplasia. 
Supplementary
